Cargando…
The blood–brain barrier significantly limits eflornithine entry into Trypanosoma brucei brucei infected mouse brain(1)
Drugs to treat African trypanosomiasis are toxic, expensive and subject to parasite resistance. New drugs are urgently being sought. Although the existing drug, eflornithine, is assumed to reach the brain in high concentrations, little is known about how it crosses the healthy and infected blood–bra...
Autores principales: | Sanderson, Lisa, Dogruel, Murat, Rodgers, Jean, Bradley, Barbara, Thomas, Sarah Ann |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2695853/ https://www.ncbi.nlm.nih.gov/pubmed/18823367 http://dx.doi.org/10.1111/j.1471-4159.2008.05706.x |
Ejemplares similares
-
Untargeted Metabolomics Reveals a Lack Of Synergy between Nifurtimox and Eflornithine against Trypanosoma brucei
por: Vincent, Isabel M., et al.
Publicado: (2012) -
Trypanosoma brucei brucei: Endocytic recycling is important for mouse infectivity
por: Natesan, Senthil Kumar A., et al.
Publicado: (2011) -
SUMOylation in Trypanosoma brucei
por: Klein, Cornelia Andrea, et al.
Publicado: (2013) -
Trypanosoma evansi is alike to Trypanosoma brucei
brucei in the subcellular localisation of glycolytic
enzymes
por: Moreno, S Andrea, et al.
Publicado: (2015) -
A multicentre, randomised, non-inferiority clinical trial comparing a nifurtimox-eflornithine combination to standard eflornithine monotherapy for late stage Trypanosoma brucei gambiense human African trypanosomiasis in Uganda
por: Kansiime, Freddie, et al.
Publicado: (2018)